Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Aventis Pharma Limited

Marion Merrell Dow Canada Inc.

Gestion De La Sante Marion Merrell Dow Canada Inc.-Marion Merrell Dow Canada Health Management Inc.

Nelsen L. Lentz

Shyam Sunder

Norton P. Peet

Nelsen L Lentz

Norton P Peet

Alan D Cardin

David R Borcherding

Philip M Weintraub

Mark W Dudley

Robert J Cregge

Philip R Kastner

Allan D Cardin

8-substituted xanthines as selective adenosine receptor agents

The compound (R)-2-[(phenylisopropyl)amino]adenosine whose structure is given below: ##STR1## (R)-2-[(phenylisopropyl)amino]adenosine is about two orders of magnitude greater in its selectivity between the A-1 and A-2 adenosine receptors than its diastereoisomer. This compound is useful for lowering blood pressure.

2-substituted adenosines with A-2 receptor affinity

Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.

Selective adenosine receptor agents

Sulfonic acid stilbenes are disclosed which block the infection of cells by HSV, HIV and CMV.

Sulfonic acid derivatives in the treatment of viral diseases

The present invention relates to certain novel 8-substituted purines as selective A.sub.1 -adenosine receptor antagonists which are useful in the treatment of patients suffering from Alzheimer's disease, congestive heart failure or pulmonary bronchoconstriction.

8-substituted purines as selective adenosine receptor agents

Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which can be expected to enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.

Tricyclic fused adenine derivatives

Selective adenosine reseptor compounds

The present invention relates to compounds which are 4-hydroxy-4-alkenylcyclohexanecarboxylic acid derivatives possessing leukotriene antagonist activity. The compounds are useful in the treatment of allergic diseases, particularly in the treatment of human asthma. They are prepared by the reaction of an appropriate oxaspiro compound with a mercaptoalkanoic acid derivative.

4-hydroxy-4-(substituted alkenyl)cyclohexanecarboxylic acids

Growing community of inventors

West Chester, OH, United States of America

Nelsen L Lentz